GSTC (GlobeStar Therapeutics) EBITDA Margin %: 0.00% (As of Jun. 2024)


What is GlobeStar Therapeutics EBITDA Margin %?

GlobeStar Therapeutics GSTC -99.00% EBITDA Margin % is 0.00% as of Jun. 2024.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. GlobeStar Therapeutics's EBITDA for the three months ended in Jun. 2024 was $-0.19 Mil. GlobeStar Therapeutics's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, GlobeStar Therapeutics's EBITDA margin for the quarter that ended in Jun. 2024 was 0.00%.

GlobeStar Therapeutics  (OTCPK:GSTC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

GlobeStar Therapeutics EBITDA Margin % Related Terms

GlobeStar Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for GlobeStar Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlobeStar Therapeutics EBITDA Margin % Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GlobeStar Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GSTC vs GBLX, ENDV, CNBX: EBITDA Margin % Comparison

For the Biotechnology subindustry, GlobeStar Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlobeStar Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeStar Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where GlobeStar Therapeutics's EBITDA Margin % falls into.


GlobeStar Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

GlobeStar Therapeutics's EBITDA Margin % for the fiscal year that ended in Sep. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Sep. 2023 )/Revenue (A: Sep. 2023 )
=-1.858/0
= %

GlobeStar Therapeutics's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-0.193/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
GlobeStar Therapeutics (GSTC) has a EBITDA Margin % of 0.00% as of Jun. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GlobeStar Therapeutics and its competitors.
Is GlobeStar Therapeutics' EBITDA Margin % too high?
GlobeStar Therapeutics' current EBITDA Margin % is 0.00%.
How does GlobeStar Therapeutics' EBITDA Margin % compare to GBLX and ENDV?
GlobeStar Therapeutics' EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GlobeStar Therapeutics and its competitors. GlobeStar Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlobeStar Therapeutics stock overvalued right now?
GlobeStar Therapeutics (GSTC) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For GlobeStar Therapeutics (GSTC), the current EBITDA Margin % is 0.00% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlobeStar Therapeutics Business Description

Address 719 Jadewin Avenue, Richland, WA, USA, 99352
GlobeStar Therapeutics Corp is a clinical-stage pharmaceutical company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.